Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

11.1%

2 terminated/withdrawn out of 18 trials

Success Rate

87.5%

+1.0% vs industry average

Late-Stage Pipeline

6%

1 trials in Phase 3/4

Results Transparency

21%

3 of 14 completed trials have results

Key Signals

3 with results

Enrollment Performance

Analytics

Phase 1
13(86.7%)
Phase 2
1(6.7%)
Phase 3
1(6.7%)
15Total
Phase 1(13)
Phase 2(1)
Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (18)

Showing 18 of 18 trials
NCT03513549Suspended

Observational Study Evaluating the Safety of ADASUVE® in Agitation Associated With Schizophrenia or Bipolar I Disorder

Role: collaborator

NCT05408663Phase 1Completed

A Phase 1 Study of EXT608 in Healthy Adults

Role: collaborator

NCT05541159Phase 1Withdrawn

Pharmacokinetics Study of TNO155 in Participants With Mild, Moderate, or Severe Renal Impairment Compared to Matched Healthy Participants

Role: collaborator

NCT05490030Phase 1Withdrawn

Pharmacokinetics of TNO155 in Participants With Mild, Moderate, or Severe Hepatic Impairment Compared to Matched Healthy Participants

Role: collaborator

NCT04470388Phase 1Completed

A Study of EDP-514 in Patients With Chronic Hepatitis B Virus Infection Who Are Not Currently on Treatment

Role: collaborator

NCT04008004Phase 1Completed

A Study of EDP-514 in Healthy Subjects (Part 1) and Patients With Chronic Hepatitis B Virus Infection (Part 2)

Role: collaborator

NCT04498741Phase 1Completed

Drug-Drug Interaction Study Between EDP-938, Tacrolimus, Dabigatran, Rosuvastatin and Midazolam in Healthy Subjects

Role: collaborator

NCT03394924Phase 2Completed

A Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of EDP-305 in Subjects With Primary Biliary Cholangitis

Role: collaborator

NCT02408523Phase 3Completed

A Study to Assess the Safety and Efficacy of Lacosamide Versus Placebo (a Pill Without Active Medication) in Patients With Idiopathic Generalised Epilepsy Who Are Already Taking Anti-epileptic Medications

Role: collaborator

NCT03986606Phase 1Unknown

A Study of PSB205 in Subjects With Advanced Solid Tumors

Role: collaborator

NCT03755778Phase 1Completed

Drug-Drug Interaction Study Between EDP-938, Itraconazole, Rifampin, and Quinidine in Healthy Subjects

Role: collaborator

NCT03750383Phase 1Completed

Drug-Drug Interaction Study Between EDP-938, Cyclosporine and Prednisone in Healthy Adult Subjects

Role: collaborator

NCT03384823Phase 1Completed

A Study of EDP-938 in Healthy Subjects

Role: collaborator

NCT02918929Phase 1Completed

A Study of EDP 305 in Healthy Subjects and Subjects With Presumptive NAFLD

Role: collaborator

NCT02788721Phase 1Completed

A Study to Assess Safety, Tolerability and Pharmacokinetics of GLPG2451 in Healthy Female Subjects

Role: collaborator

NCT01242696Completed

TAXUS® Element™ Paclitaxel-Eluting Coronary Stent System European Post-Approval Surveillance Study (TE-Prove)

Role: collaborator

NCT01148329Completed

PROMUS™ Element™ Everolimus-Eluting Coronary Stent System European Post-Approval Surveillance Study

Role: collaborator

NCT02306629Phase 1Completed

Study to Compare Properties of Epratuzumab When Given as an Injection Under the Skin or Directly Into the Blood

Role: collaborator

All 18 trials loaded